openPR Logo
Press release

CRISPR therapies Pipeline Assessment - FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies by DelveInsight

09-06-2022 09:38 AM CET | Health & Medicine

Press release from: DelveInsight

CRISPR therapies Pipeline

CRISPR therapies Pipeline

CRISPR therapies pipeline constitutes 25+ key companies continuously working towards developing 30+ CRISPR therapies treatment therapies, analyzes DelveInsight

CRISPR-Cas is an adaptive immune system existing in most bacteria and archaea, preventing them from being infected by phages, viruses and other foreign genetic elements. It is composed of CRISPR repeat-spacer arrays, which can be further transcribed into CRISPR RNA (crRNA) and trans-activating CRISPR RNA (tracrRNA), and a set of CRISPR-associated (cas) genes which encode Cas proteins with endonuclease activity.

"CRISPR therapies Pipeline Insight, 2022" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the CRISPR therapies Market.
The CRISPR therapies Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

To know more about the CRISPR therapies pipeline report, click here: https://www.delveinsight.com/report-store/crispr-therapies-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

DelveInsight's CRISPR therapies Report covers around 30+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Emerging CRISPR therapies Under Different Phases of Clinical Development Include:
• CTX001: CRISPR Therapeutics
• EDIT-101: Editas Medicine
And Many Others.

Further CRISPR therapies product details are provided in the report. Download the CRISPR report to learn more about the emerging CRISPR therapies at: https://www.delveinsight.com/sample-request/crispr-therapies-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

CRISPR therapies Pipeline Analysis
The CRISPR therapies report provides insights into:
The report provides detailed insights about companies that are developing therapies for the treatment of CRISPR therapies with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the CRISPR therapies Treatment.
CRISPR therapies key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
CRISPR therapies Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the CRISPR therapies market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Request for Sample PDF Report for CRISPR therapies pipeline assessment- https://www.delveinsight.com/sample-request/crispr-therapies-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key companies in the CRISPR therapies Therapeutics Market:
Some of the CRISPR companies working in the market are Intellia Therapeutics, CRISPR therapeutics, Repare Therapeutics, Beam therapeutics, Caribou Biosciences, Emendo Biotherapeutics, Defence Therapeutics, Sarepta therapeutics, Editas Medicine, Locus Biosciences, Excision BioTherapeutics, AstraZeneca, Novartis, ASC therapeutics, Casebia therapeutics, Spotlight Therapeutics,KSQ Therapeutics, MEDIC Life Sciences, Scribe therapeutics, Arbor Biotechnologies, Sangamo therapeutics,Graphite Bio, Nuntius Therapeutics.

Request for Sample PDF Report to know more about the CRISPR therapies and drugs- https://www.delveinsight.com/sample-request/crispr-therapies-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. CRISPR therapies Current Treatment Patterns
4. CRISPR therapies - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. CRISPR therapies Late Stage Products (Phase-III)
7. CRISPR therapies Mid-Stage Products (Phase-II)
8. CRISPR therapies Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. CRISPR therapies Discontinued Products
13. CRISPR therapies Product Profiles
14. Key Companies in the CRISPR therapies Market
15. Key Products in the CRISPR therapies Therapeutics Segment
16. Dormant and Discontinued Products
17. CRISPR therapies Unmet Needs
18. CRISPR therapies Future Perspectives
19. CRISPR therapies Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know in detail about the CRISPR therapies clinical trials and advancements - https://www.delveinsight.com/sample-request/crispr-therapies-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Trending Reports:
• T-Cell-Prolymphocytic Leukemia Market: https://www.delveinsight.com/report-store/t-cell-prolymphocytic-leukemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
• Bone Grafts And Substitutes Market: https://www.delveinsight.com/report-store/bone-grafts-and-substitutes-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
• Hip Replacement Devices Market: https://www.delveinsight.com/report-store/hip-reconstruction-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
• Hepatic Encephalopathy Epidemiology Forecast: https://www.delveinsight.com/report-store/hepatic-encephalopathy-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
• Familial Primary Pulmonary Hypertension Market: https://www.delveinsight.com/report-store/familial-primary-pulmonary-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
• Global Electrophysiology Devices Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
• Age Related Vision Dysfunction Market: https://www.delveinsight.com/report-store/age-related-vision-dysfunction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
• Emesis Market: https://www.delveinsight.com/report-store/emesis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release CRISPR therapies Pipeline Assessment - FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies by DelveInsight here

News-ID: 2725051 • Views:

More Releases from DelveInsight

Insulin Resistance Pipeline Insight 2025: Pipeline Drugs, Metabolic Pathway Modulators, and Novel Therapeutics Redefine Future Care | DelveInsight
Insulin Resistance Pipeline Insight 2025: Pipeline Drugs, Metabolic Pathway Modu …
DelveInsight's "Insulin Resistance - Pipeline Insight, 2025" explores over 10+ therapies in development for insulin resistance, a metabolic condition strongly linked to type 2 diabetes, obesity, and cardiovascular disease. Despite lifestyle modification and insulin-sensitizing drugs like metformin being mainstays of management, many patients continue to face poor glycemic control and associated complications, underscoring the need for more effective insulin resistance treatments. The insulin resistance pipeline is broadening with next-generation therapies targeting
Uveal Melanoma Pipeline Insight 2025: 30+ Pipeline Drugs, Targeted Therapies, and Immuno-Oncology Strategies Drive Innovation | DelveInsight
Uveal Melanoma Pipeline Insight 2025: 30+ Pipeline Drugs, Targeted Therapies, an …
DelveInsight's "Uveal Melanoma - Pipeline Insight, 2025" explores over 30+ therapies in development for uveal melanoma, a rare and aggressive intraocular malignancy with high metastatic potential, most commonly to the liver. Despite surgery and radiotherapy being standards for localized disease, patients with metastatic uveal melanoma face limited systemic treatment options, creating significant unmet needs in the uveal melanoma treatment landscape. The uveal melanoma pipeline is diversifying with next-generation targeted therapies, including
Peptic Ulcers Pipeline Insight 2025: Emerging Therapies and Clinical Trials Shaping Next-Generation Peptic Ulcer Disease Treatments | DelveInsight
Peptic Ulcers Pipeline Insight 2025: Emerging Therapies and Clinical Trials Shap …
DelveInsight's "Peptic Ulcers - Pipeline Insight, 2025" examines over 8+ therapies in development for peptic ulcer disease, a condition affecting millions worldwide with peptic ulcer disease symptoms such as abdominal pain, bloating, nausea, and gastrointestinal bleeding. Despite widespread use of existing peptic ulcer disease treatments, including proton pump inhibitors, H2 blockers, and antibiotics for H. pylori eradication, patients with recurrent or complicated peptic ulcers continue to face significant unmet needs,
Vaso-Occlusive Crisis in Sickle Cell Disease: Emerging Therapies, Clinical Trials, and Pipeline Innovations Shaping the Future of Treatment - 2025 | DelveInsight
Vaso-Occlusive Crisis in Sickle Cell Disease: Emerging Therapies, Clinical Trial …
DelveInsight's "Vaso-Occlusive Crisis (VOC) Associated With Sickle Cell Disease - Pipeline Insight, 2025" provides an in-depth analysis of emerging therapies targeting vaso-occlusive crisis (VOC), a severe and recurring complication of sickle cell disease. Despite current standards of care, including hydroxyurea, patients continue to experience frequent vaso occlusive sickle cell crisis, underscoring the urgent need for effective interventions in sickle cell anemia vaso occlusive crisis treatment. The VOC pipeline is diversifying with

All 5 Releases


More Releases for CRISPR

Amerigo Scientific Unveils CRISPR/Cas Enzymes to Expand the CRISPR Toolbox
Amerigo Scientific, as a distributor focused on providing critical products and services to biomedical and life science communities, announced the release of a groundbreaking selection of CRISPR/Cas enzymes to its extensive life science portfolio, aimed at further expanding the vast potential of the CRISPR toolbox. This addition brings cutting-edge genetic editing tools to scientists and researchers in a variety of fields. CRISPR/Cas (Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR-associated) technology revolutionized the
CRISPR Technology Market - Gene Editing Redefined: Pioneering CRISPR Technology …
Newark, New Castle, USA: The "CRISPR Technology Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors CRISPR Technology Market: https://www.growthplusreports.com/report/crispr-technology-market/7632 This latest report researches the industry structure, sales,
CRISPR And CRISPR-Associated (Cas) Genes Market Analysis & Trends - Industry For …
LOS ANGELES, United States: The research study presented in this report offers a complete and intelligent analysis of the competition, segmentation, dynamics, and geographical advancement of the global CRISPR And CRISPR-Associated (Cas) Genes market. It takes into account the CAGR, value, volume, revenue, production, consumption, sales, manufacturing cost, prices, and other key factors related to the global CRISPR And CRISPR-Associated (Cas) Genes market. The authors of the report have segmented
CRISPR & Cas Genes Market Dynamic Growth Factors 2028 | CRISPR Therapeutics, Ast …
"CRISPR & Cas Genes Market" Report offers an in-depth analysis of the market size, share, SWOT Analysis, future progress expansion, industry growth, key development strategies and market trend dynamics which includes drivers, restraints, opportunities prevailing in the industry by product type, application, key manufacturers and key regions and countries. It also offers advanced statistics as well as some business-driven information associated with the precise industry. It delivers an analytical investigation of the
CRISPR and CRISPR-Associated (Cas) Genes Market 2022 | Detailed Report
According to Market Study Report, CRISPR and CRISPR-Associated (Cas) Genes Market provides a comprehensive analysis of the CRISPR and CRISPR-Associated (Cas) Genes Market segments, including their dynamics, size, growth, regulatory requirements, competitive landscape, and emerging opportunities of global industry. An exclusive data offered in this report is collected by research and industry experts team. Download FREE Sample Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=4240401 The report provides a comprehensive analysis of company profiles listed below: -
CRISPR and CRISPR-Associated (Cas) Genes Market 2021 | Detailed Report
The CRISPR and CRISPR-Associated (Cas) Genes research report undoubtedly meets the strategic and specific needs of the businesses and companies. The report acts as a perfect window that provides an explanation of market classification, market definition, applications, market trends, and engagement. The competitive landscape is studied here in terms of product range, strategies, and prospects of the market’s key players. Furthermore, the report offers insightful market data and information about